Algert Global’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Algert Global's TRDA Position: Q3 2026 in Review
Algert Global opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 13,820 shares worth $87.8K. The stake represents ﹤0.01% of the portfolio and ranks #1282 among its holdings. This is a return to the name: Algert Global previously reported a position in TRDA as recently as Q4 2025.
Algert Global first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.32M in Q4 2025. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- Algert Global held 13,820 shares of Entrada Therapeutics worth $87.8K as of Q3 2026.
- Entrada Therapeutics was a new Algert Global position in Q3 2026.
- Entrada Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q3 2026, its #1282 holding.
- Algert Global first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
- Algert Global's Entrada Therapeutics position peaked at $1.32M in Q4 2025.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on Algert Global's 13F filing for Q3 2026, filed 17 Nov 2026.